Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Baolingbao Biology Co.,Ltd. (002286.SZ)
Yucheng, CN
Established in 1997 and headquartered in Yucheng, China, Baolingbao Biology Co.,Ltd. specializes in the production of a wide array of corn-based ingredients for health and food industries, serving both domestic and international markets. Its diverse product range includes various oligosaccharides like isomalto-oligosaccharide, galacto-oligosaccharides, and fructose-oligosaccharides, as well as erythritol. The company also provides a selection of sweeteners such as high fructose corn syrups, crystalline fructose, and sugar alcohols. Furthermore, it offers specialized fibers like resistant dextrin-soluble corn fiber and polydextrose, alongside starch sugars including trehalose, maltodextrin, and glucose syrup. Completing its portfolio are certain finished goods and valuable corn by-products like corn steep liquors, corn husk sprayed products, and corn gluten meal. These versatile ingredients are widely utilized across numerous applications, from beverages, dairy, bakery, confectionery, meat, honey, seafood, canned foods, and condiments, to health foods, infant nutrition, fermentation, and animal feed. Beyond the food sector, their applications extend to daily chemicals, pharmaceuticals, and cosmetics.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.61% | +4.33% | -9.93% | -17.63% | +0.88% | +2.46% | -23.79% | +10.36% | -23.67% | -32.80% | +2.81% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+14.5% ★ Q1'26: +9.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+36.7% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+3.6% Q1'26: -11.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+6.8% ★ Q1'26: +9.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+7.7% ★ Q1'26: +10.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.9% ★ Q1'26: +7.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.34× ★ Q1'26: 0.77× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.20B
est: 1.20B (+0.0%)
|
1.38B
est: 1.38B (-0.2%)
|
1.59B
est: 1.67B (-4.7%)
|
1.73B
est: 2.04B (-15.2%)
|
1.81B
est: 2.45B (-26.4%)
|
2.05B
est: 2.20B (-6.8%)
|
2.60B
est.
|
2.76B
est: 3.78B (-26.9%)
|
2.71B
est: 4.69B (-42.2%)
|
2.52B
est: 4.69B (-46.2%)
|
2.40B
est: 5.43B (-55.8%)
|
2.75B
est: 2.54B (+8.4%)
|
3.05B
3.05B – 3.05B
+20.2% YoY
|
3.33B
3.33B – 3.33B
+9.1% YoY
|
3.58B
3.58B – 3.58B
+7.7% YoY
|
| EBITDA |
111.87M
est: 124.55M (-10.2%)
|
142.47M
est: 143.72M (-0.9%)
|
141.82M
est: 174.02M (-18.5%)
|
165.87M
est: 212.55M (-22.0%)
|
175.68M
est: 255.46M (-31.2%)
|
169.07M
est: 229.54M (-26.3%)
|
270.77M
est.
|
358.67M
est: 393.75M (-8.9%)
|
286.17M
est: 488.90M (-41.5%)
|
207.19M
est: 488.90M (-57.6%)
|
263.17M
est: 584.92M (-55.0%)
|
307.23M
est: 273.37M (+12.4%)
|
328.62M
328.62M – 328.62M
+20.2% YoY
|
358.46M
358.46M – 358.46M
+9.1% YoY
|
386.03M
386.03M – 386.03M
+7.7% YoY
|
| EBIT |
55.69M
est: 69.04M (-19.3%)
|
64.11M
est: 79.67M (-19.5%)
|
64.48M
est: 96.46M (-33.2%)
|
82.13M
est: 117.82M (-30.3%)
|
77.45M
est: 141.61M (-45.3%)
|
72.81M
est: 127.24M (-42.8%)
|
150.09M
est.
|
253.69M
est: 218.26M (+16.2%)
|
184.74M
est: 271.01M (-31.8%)
|
89.35M
est: 271.01M (-67.0%)
|
145.03M
est: 351.44M (-58.7%)
|
186.92M
est: 164.25M (+13.8%)
|
197.45M
197.45M – 197.45M
+20.2% YoY
|
215.38M
215.38M – 215.38M
+9.1% YoY
|
231.95M
231.95M – 231.95M
+7.7% YoY
|
| Net Income |
40.95M
est: 46.22M (-11.4%)
|
49.34M
est: 66.56M (-25.9%)
|
49.62M
est: 59.16M (-16.1%)
|
42.95M
est: 73.95M (-41.9%)
|
35.23M
est: 85.05M (-58.6%)
|
49.86M
est: 299.51M (-83.4%)
|
199.67M
est.
|
201.58M
est: 284.72M (-29.2%)
|
133.17M
est: 362.37M (-63.3%)
|
53.97M
est: 362.37M (-85.1%)
|
111.16M
est: 429.84M (-74.1%)
|
150.63M
est: 176.34M (-14.6%)
|
194.71M
194.71M – 194.71M
+10.4% YoY
|
246.15M
246.15M – 246.15M
+26.4% YoY
|
319.62M
319.62M – 319.62M
+29.9% YoY
|
| SGA |
122.49M
est: 22.91M (+434.7%)
|
151.83M
est: 26.43M (+474.4%)
|
143.15M
est: 32.01M (+347.2%)
|
160.02M
est: 39.10M (+309.3%)
|
173.38M
est: 46.99M (+269.0%)
|
98.68M
est: 42.22M (+133.7%)
|
49.80M
est.
|
121.14M
est: 72.42M (+67.3%)
|
128.77M
est: 89.92M (+43.2%)
|
105.69M
est: 89.92M (+17.5%)
|
105.27M
est: 221.18M (-52.4%)
|
73.33M
est: 103.37M (-29.1%)
|
124.26M
124.26M – 124.26M
+20.2% YoY
|
135.55M
135.55M – 135.55M
+9.1% YoY
|
145.97M
145.97M – 145.97M
+7.7% YoY
|
| EPS |
0.11
est: 0.13 (-12.0%)
|
0.13
est: 0.18 (-27.8%)
|
0.13
est: 0.16 (-18.8%)
|
0.12
est: 0.20 (-40.0%)
|
0.10
est: 0.23 (-56.5%)
|
0.14
est: 0.81 (-82.7%)
|
0.54
est.
|
0.54
est: 0.77 (-29.9%)
|
0.36
est: 0.98 (-63.3%)
|
0.15
est: 0.98 (-84.7%)
|
0.30
est: 1.17 (-74.4%)
|
0.41
est: 0.48 (-14.6%)
|
0.53
0.53 – 0.53
+10.4% YoY
|
0.67
0.67 – 0.67
+26.4% YoY
|
0.87
0.87 – 0.87
+29.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Liu | Executive Deputy GM & Non-Independent Director | — | male |
| Qiang Wang | GM & Director | — | male |
| Wen Xiu Wen | Accounting Supervisor | — | female |
| Xia Li | Deputy General Manager | — | female |
| Yanjun Wang | Deputy General Manager | — | male |
| Zhe Zhu | Secretary to the Board | — | male |
| Zhou Yu | Financial Director & Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002286.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
